Sep 8, 2026

Featuring perspectives from Dr William K Oh and Dr Mary-Ellen Taplin, including the following topics:

• Introduction: Another Perspective on the Treatment of Localized Prostate Cancer (0:00)
• Nonmetastatic Disease (10:32)
• Metastatic Androgen Pathway Modulation-Naïve and Androgen Pathway Modulation-Sensitive Disease...

Sep 7, 2026

Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:

• Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune...

Sep 6, 2026

Featuring perspectives from Prof John Seymour, including the following topics:

• Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)
• Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21)
• First-line treatment with sonrotoclax and zanubrutinib...

Sep 5, 2026

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:

• Tolerability of capivasertib and management of associated side effects — Question from Neeraj Agarwal, MD, FASCO (0:00)
• Case: A man in his early 70s with Type 2 diabetes...

Sep 3, 2026

Featuring perspectives from Dr Lisa A Carey and Dr Maha Hussain, including the following topics:

• Introduction (0:00)
• HER2 History (1:32)
• Cases from the GMO Survey (7:06)
• Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) — Dr Mahtani (19:56)
• Faculty Case...